Missouri attorney general takes new legal aim at mail-order abortion pills over safety concerns
Missouri Attorney General Catherine Hanaway is intensifying efforts against mail-order abortion pills by challenging the recent FDA approval of a generic mifepristone. She argues that the drug, which is linked to serious health risks and complications, is entering the market without necessary medical safeguards, thus endangering women's health. This lawsuit is part of a broader multi-state initiative aimed at reinstating pre-2016 safety standards and halting the distribution of these pills without in-person medical evaluations. Hanaway's actions reflect ongoing Republican concerns regarding the FDA's oversight of abortion medications. Looking ahead, Missouri, alongside Kansas and Idaho, seeks judicial intervention to protect women's health amid shifting regulatory landscapes.
Dive Deeper:
Catherine Hanaway claims that the generic mifepristone, produced by Evita Solutions, leads to life-threatening complications for women and lacks essential medical oversight, often resulting in hospitalizations.
The lawsuit highlights that federal law prohibits mailing abortion drugs, yet a network of distributors has circumvented this by offering pills without necessary medical checks, raising safety concerns.
Missouri's legal challenge aims to block the FDA's approval of the generic mifepristone and restore safety protocols that mandate in-person medical evaluations for women seeking abortions.
Hanaway noted that approximately 1 in 25 women using chemical abortion drugs experience emergency medical issues, emphasizing the heightened risks associated with mail-order services.
Republican lawmakers, including Senator Josh Hawley, are advocating for stricter FDA regulations on abortion medications, reflecting broader political pressures on health policy regarding reproductive rights.
The FDA's approval process for mifepristone has come under scrutiny, with lawmakers questioning its partnerships with drug manufacturers like Evita Solutions, highlighting concerns over the safety and efficacy of these medications.
Evita Solutions has not publicly responded to inquiries regarding the lawsuit and the allegations concerning the safety of its product.